Clinical Outcomes of Early Antiviral Intervention in Viral Pneumonia

Abstract

Viral pneumonia continues to be one of the most frequent reasons for hospital admission around the world, and the clinical toll it extracts is substantial. Influenza A and B, respiratory syncytial virus (RSV), SARS-CoV-2, and parainfluenza viruses together make up roughly 70% of community-acquired viral pneumonia cases in adults. There has been growing interest in whether starting antiviral drugs early -- specifically within the first 48 hours after symptoms appear -- can meaningfully reduce how sick patients get, how long they stay in hospital, and ultimately whether they survive. Yet the evidence has been scattered across pathogen-specific studies, and nobody has really pulled it all together in a single multicentre European cohort. We carried out a retrospective study involving six tertiary hospitals in Vienna, Tallinn, Berlin, Prague, Zurich, and Copenhagen, looking at 1,248 adults admitted with RT-PCR-confirmed viral pneumonia from January 2019 through December 2021. We split them into two groups: those who got antivirals within 48 hours of symptom onset (n = 614) and those who started later (n = 634). What we found was striking. The early treatment group had noticeably lower 30-day mortality (8.3% versus 15.6%, adjusted OR 0.48, 95% CI 0.34-0.68, p < 0.001), fewer ICU admissions (18.2% versus 29.7%, p < 0.001), shorter hospital stays (median 7.4 versus 11.8 days, p < 0.001), and quicker viral clearance (4.2 versus 7.1 days, p < 0.001). We developed an Antiviral Timing Benefit Score (ATBS) that pulls together mortality, ICU avoidance, length-of-stay, and viral clearance into a single metric. The highest scores went to oseltamivir for influenza (ATBS 0.91) and remdesivir for SARS-CoV-2 (ATBS 0.87). The take-home message is clear: getting the right antiviral started quickly makes a real, measurable difference in patient outcomes.